P J Jost
Overview
Explore the profile of P J Jost including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jahn A, Rump A, Widmann T, Heining C, Horak P, Hutter B, et al.
Ann Oncol
. 2022 Aug;
33(11):1186-1199.
PMID: 35988656
Background: Germline variant evaluation in precision oncology opens new paths toward the identification of patients with genetic tumor risk syndromes and the exploration of therapeutic relevance. Here, we present the...
2.
Riedmann K, Bassermann F, Jost P
Internist (Berl)
. 2019 Mar;
60(5):540-544.
PMID: 30859279
Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various...
3.
Fernandez-Marrero Y, Spinner S, Kaufmann T, Jost P
Leukemia
. 2016 Aug;
30(11):2152-2159.
PMID: 27479182
Programmed apoptotic cell death is critical to maintain tissue homeostasis and cellular integrity in the lymphatic system. Accordingly, the evasion of apoptosis is a critical milestone for the transformation of...
4.
Spinner S, Crispatzu G, Yi J, Munkhbaatar E, Mayer P, Hockendorf U, et al.
Leukemia
. 2016 Apr;
30(7):1520-30.
PMID: 27055871
T lymphocyte non-Hodgkin's lymphoma (T-NHL) represents an aggressive and largely therapy-resistant subtype of lymphoid malignancies. As deregulated apoptosis is a frequent hallmark of lymphomagenesis, we analyzed gene expression profiles and...
5.
Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U, et al.
Leukemia
. 2015 Jul;
30(1):112-23.
PMID: 26153654
Deregulated apoptosis is an identifying feature of myelodysplastic syndromes (MDS). Whereas apoptosis is increased in the bone marrow (BM) of low-risk MDS patients, progression to high-risk MDS correlates with an...
6.
Galluzzi L, Bravo-San Pedro J, Vitale I, Aaronson S, Abrams J, Adam D, et al.
Cell Death Differ
. 2014 Sep;
22(1):58-73.
PMID: 25236395
Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally...
7.
Kaufmann T, Strasser A, Jost P
Cell Death Differ
. 2011 Oct;
19(1):42-50.
PMID: 21959933
Fas (also called CD95 or APO-1), a member of a subgroup of the tumour necrosis factor receptor superfamily that contain an intracellular death domain, can initiate apoptosis signalling and has...
8.
Bianchi K, Jost P, Kaufmann T, Rutkowski R
Cell Death Differ
. 2009 Jul;
16(8):1180-3.
PMID: 19597461
No abstract available.
9.
Nieder C, Jost P, Grosu A, Peschel C, Molls M
Breast
. 2003 Dec;
12(5):345-7.
PMID: 14659151
As in female patients, the clinical course in male patients with breast cancer is determined mainly by tumor stage. The literature contains very limited data on either the occurrence or...
10.
Jost P, Harbottle R, Knight A, Miller A, Coutelle C, Schneider H
FEBS Lett
. 2001 Feb;
489(2-3):263-9.
PMID: 11165262
Targeting gene vectors to human airway epithelial cells may help to overcome the current inefficiency of gene transfer as the major problem confronting cystic fibrosis gene therapy. To elucidate novel...